RxDoctor Payments Data

Scott Shorten, MD

Sleep Medicine · North Kansas City, MONPI 1679884704

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,638 of the $1,997 with a category attached, or 82.0%. It is spread thinly across 37 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $747 and has fallen 57.4% since, to $318 in 2024.

$1,997in general payments, 2019–2025

Across 93 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$409
  • AbbVie$392
  • Novartis$164
  • Jazz Pharmaceuticals Inc.$116
  • Tersera Therapeutics LLC$80
  • Arbor Pharmaceuticals, Inc.$59
  • plus $778 from 31 others

What the payments were for

  • Speaking & faculty fees$211%
  • Food & beverage$1,63882%
  • Education$33817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,997 in reported general payments places this provider in the 70th percentile of 33 sleep medicine providers in Missouri.

See all sleep medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$47,781
Medicare patients
250
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant46$33,875
UbrelvyUbrogepant12$11,443
DayvigoLemborexant20$9,732
Pregabalin136$5,396
Gabapentin258$4,813
Temazepam85$4,158
Memantine Hcl66$4,136
Ropinirole Hcl107$3,921
Zaleplon96$3,092
Triazolam25$2,894
Pramipexole DihydrochloridePramipexole Di-Hcl87$2,284
Modafinil39$1,965
Propranolol Hcl ErPropranolol Hcl28$1,808
Carbidopa-LevodopaCarbidopa/Levodopa43$1,797
Duloxetine Hcl45$1,498

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$392$11,44312 claims
Upsher-smith Laboratories LLCTopiramate$22$48622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 33 sleep medicine providers in Missouri.

Other sleep medicine in North Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →